Curaleaf International Takes Over Can4Med, a Polish Medical Cannabis Wholesaler

Curaleaf International, a Curaleaf Holdings company and Europe’s largest vertically integrated cannabis company, announced the acquisition of Can4Med, a leading medical cannabis wholesaler in Poland.

This strategic move represents a “significant milestone” for both companies and underlines Curaleaf’s commitment to improving patient access to high-quality medical cannabis products across Europe. Poland has one of the largest populations of medical cannabis patients in Europe.

Read more about the acquisition of Can4Med by Curaleaf and find the latest financial news of the day with our companion app Born2Invest.

Curaleaf enters the medical cannabis market in Poland

By joining forces with Can4Med, Curaleaf International is gaining a strong position in this dynamic market, which will allow it to expand its product offer on the Polish market.

“This acquisition represents a significant step forward for Curaleaf International. The medical cannabis market in Poland is growing rapidly, and our collaboration with Can4Med will allow us to better serve patients while driving growth throughout Europe,” said Matt Darin, CEO of Curaleaf.

“We are thrilled that Can4med, a driving force in the cannabis market in Poland, has joined forces with Curaleaf, a global leader in the cannabis industry. This acquisition represents a significant milestone in our journey, providing an unrivaled supply chain that positions us to meet and exceed the expectations of the entire Polish market. The partnership with Curaleaf not only reinforces our commitment to quality and availability, but also represents a new era of growth and opportunity for both companies and our customers,” said Maximilian Weinberg, founder of Can4med.

Medical cannabis market in Poland

Positioning itself at the forefront of the European cannabis market, with a population of 38 million citizens, Poland is ready for a significant increase in innovation in this sector.

The Polish Pharmaceutical Chamber estimates that the potential number of medical cannabis users could reach 300,000, while the number of legal cannabis users (both medical and CBD ) is expected to reach 1.3 million by 2026.

Three tons of medical cannabis in 2023

In 2023 alone, Poland imported over 3,000 kg of cannabis to Poland, which reflects the growing acceptance and recognition of its therapeutic benefits. This development is supported by an extensive network of cannabis clinics authorized to prescribe cannabis.

Despite the complex registration process that manufacturers and patients must undergo, Curaleaf International, through its subsidiary Four 20 Pharma GmbH, has emerged as a leading force, securing its position as one of the licensed manufacturers in the Polish market.

About Curaleaf and Can4Med

Curaleaf International , a subsidiary of Curaleaf Holdings, is Europe’s largest vertically integrated cannabis company. With a strong history of product innovation and regulatory compliance, Curaleaf International has established itself as a trusted supplier of cannabis-based medicines in key European markets.

Can4Med is a pharmaceutical wholesaler specializing in the purchase, registration and distribution of medical cannabis and products containing THC and other cannabinoids in Poland. The company’s focus on the import and distribution of cannabinoid medicines has positioned it as a key link in the supply chain, ensuring patients have access to safe and effective therapies.

Can4Med has a pharmaceutical wholesaler license, which allows the marketing and distribution of cannabis for medical purposes and enables the wholesale sale of medicinal products and pharmaceutical raw materials on prescription.

__

(Featured image by Budding . via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Fakty Konopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us